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https://doi.org/10.1053/j.gastro.2017.09.008BACKGROUND & AIMS: Fibrolamellar hepatocellular carci-
noma (FL-HCC) is a primary liver cancer that predominantly
affects children and young adults with no underlying liver
disease. A somatic, 400 Kb deletion on chromosome 19 that
fuses part of the DnaJ heat shock protein family (Hsp40)
member B1 gene (DNAJB1) to the protein kinase cAMP-
activated catalytic subunit alpha gene (PRKACA) has been
repeatedly identiﬁed in patients with FL-HCC. However, the
DNAJB1–PRKACA gene fusion has not been shown to induce
liver tumorigenesis. We used the CRISPR/Cas9 technique to
delete in mice the syntenic region on chromosome 8 to create
a Dnajb1–Prkaca fusion and monitored the mice for liver
tumor development. METHODS: We delivered CRISPR/Cas9
vectors designed to juxtapose exon 1 of Dnajb1 with exon 2 of
Prkaca to create the Dnajb1–Prkaca gene fusion associated
with FL-HCC, or control Cas9 vector, via hydrodynamic tail
vein injection to livers of 8-week-old female FVB/N mice.
These mice did not have any other engineered genetic
alterations and were not exposed to liver toxins or carcino-
gens. Liver tissues were collected 14 months after delivery;
genomic DNA was analyzed by PCR to detect the
Dnajb1–Prkaca fusion, and tissues were characterized by
histology, immunohistochemistry, RNA sequencing, and
whole-exome sequencing. RESULTS: Livers from 12 of the 15
mice given the vectors to induce the Dnajb1–Prkaca gene
fusion, but none of the 11 mice given the control vector,
developed neoplasms. The tumors contained the Dnajb1–
Prkaca gene fusion and had histologic and cytologic features
of human FL-HCCs: large polygonal cells with granular,
eosinophilic, and mitochondria-rich cytoplasm, prominent
nucleoli, and markers of hepatocytes and cholangiocytes. In
comparing expression levels of genes between the mouse
tumor and non-tumor liver cells, we identiﬁed changes
similar to those detected in human FL-HCC, which included
genes that affect cell cycle and mitosis regulation. Genomic
analysis of mouse neoplasms induced by the Dnajb1–Prkaca
fusion revealed a lack of mutations in genes commonly
associated with liver cancers, as observed in human FL-HCC.
CONCLUSIONS: Using CRISPR/Cas9 technology, we found
generation of the Dnajb1–Prkaca fusion gene in wild-type
mice to be sufﬁcient to initiate formation of tumors that
have many features of human FL-HCC. Strategies to blockDNAJB1–PRKACA might be developed as therapeutics for this
form of liver cancer.Keywords: Liver Cancer; Protein Kinase A; PKA; Genomic
Engineering; Mouse Model.
ibrolamellar hepatocellular carcinoma (FL-HCC) is aFrare form of liver cancer that typically arises in
children and young adults with no history of cirrhosis or
other liver diseases.1 The cancer carries high mortality, with
5-year survival below 45%.2 Surgery is presently the only
effective therapy if the cancer is diagnosed before the
occurrence of metastases, and long-term survival is jeop-
ardized by tumor recurrence.2 FL-HCC has pathodiagnostic
features distinct from the predominant liver cancers,
classical hepatocellular carcinoma (HCC), and chol-
angiocarcinoma, which include large eosinophilic and
mitochondria-rich polygonal cells with prominent nucleoli
and lamellar bands of ﬁbrosis.3,4 FL-HCC expresses markers
for hepatic progenitor, biliary, and hepatocytic lineages;
however, none of these are speciﬁc for this tumor.5,6
The molecular basis of FL-HCC has been enigmatic
because none of themajor drivers of other liver cancers, as for
EDITOR’S NOTES
BACKGROUND AND CONTEXT
A somatic chromosomal deletion that generates a chimeric
DNAJB1–PRKACA gene fusion has been repeatedly
identiﬁed in patients with ﬁbrolamellar hepatocellular
carcinoma, but its role in liver tumorigenesis has never
been demonstrated.
NEW FINDINGS
TheDnajb1–Prkacagene fusion generatedsomatically in the
liver of adult wild-type mice by CRISPR/Cas9 technique is
sufﬁcient to initiate tumorigenesis and to induce liver
tumors with cytological, histological and molecular
features of ﬁbrolamellar hepatocellular carcinoma.
LIMITATIONS
This study did not identify a mechanism where by the
gene fusion initiates tumorigenesis.
IMPACT
The study suggests DNAJB1–PRKACA as an attractive
therapeutic target for developing therapies for ﬁbrolamellar
hepatocellular carcinoma.
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FL-HCC. Recently, however, a w400 kilobase (Kb) somatic
deletion on chromosome 19was identiﬁed in primary tumor
samples from FL-HCC patients.7,8 The deletion involves
breakpoints that are positioned within intron 1, or less
frequently within exon 2, of DNAJB1, which encodes a heat
shock 40 protein family member, and within intron 1 of
PRKACA, which encodes the adenosine 30,50-monophosphate
(cAMP)-dependent protein kinase A (PKA) catalytic subunit
alpha. The deletion generates a fusion gene encompassing
exon 1 (and in fewer cases a portion of exon 2) of DNAJB1
and exons 2–10 of PRKACA, producing a chimeric protein
that retains PKA kinase activity.7,8 Interestingly, the fusion
gene is the only known recurrent genomic aberration in FL-
HCC, where it has been identiﬁed in 80–100% of patients in
various studies. By contrast, this aberration has not been
reported in any other cancer.7,9,10 Mutations in other genes
have been detected in FL-HCC tumors along with the
DNAJB1–PRKACA alteration.8,11,12 However, at present, it
remains to be established whether any of the genes found
mutated in FL-HCC, most notably the DNAJB1– PRKACA
fusion, may have a causative role.
Determining if DNAJB1–PRKACA is capable of initiating
tumor formation is an outstanding question regarding the
molecular basis of FL-HCC because this would establish
the principal genetic origin of this cancer and identify the
fusion protein as a candidate for new targeted therapies. To
address this issue, we engineered the ﬁrst FL-HCC mouse
model by using the CRISPR/Cas9 technique (clustered
regularly interspaced short palindromic repeats/CRISPR-
associated 9) to elicit in mice the w400 Kb chromosomal
deletion that creates the DNAJB1–PRKACA fusion in patients.
In addition to modeling the exact genomic alteration, we
took several other measures to better mimic human FL-HCC.
First, because DNAJB1–PRKACA mutation is somatic, weengineered this alteration in the liver of young adult mice
through hydrodynamic tail vein delivery of the CRISPR/
Cas9 reagents. Second, because we anticipated a low efﬁ-
ciency of the complex engineering task, we mirrored the
stochastic and isolated mutational events that occur natu-
rally during tumor formation. Third, because FL-HCC arises
in healthy liver, we did not challenge the mice with any liver
toxin, as for example CCl4, which is otherwise frequently
used to enhance liver cancer by damaging the liver and
mimicking liver disease.13 Finally, to best test DNAJB1–
PRKACA as a potentially sole genetic driver, we engineered
the aberration in a wild-type mouse genetic background,
nor did we treat the mice with any mutagen such as
Diethylnitrosamine (DEN), which is often used to increase
tumor susceptibility and produce a cancer phenotype, when
testing a new, candidate cancer gene in genetically engi-
neered mouse models.13
Strikingly, the Dnajb1–Prkaca engineered mice devel-
oped tumors with high frequency that replicated human
FL-HCC, as scored on several cytological and histological
parameters. Furthermore, similar to human FL-HCC, we
found no evidence of other plausible co-driver mutations in
Dnajb1–Prkaca–elicited tumors.
Our ﬁndings demonstrate that the DNAJB1–PRKACA
genomic alteration is sufﬁcient to initiate and progress
oncogenic transformation in FL-HCC. Together with the
presence of the gene fusion in nearly all FL-HCC
patients, our data strongly supports DNAJB1–PRKACA as
the driver and speciﬁc diagnostic biomarker in FL-HCC.
Furthermore, the fusion may constitute a promising
and possibly sole candidate for targeted therapies in
this cancer.Materials and Methods
Generation of gRNA Constructs for Engineering
the Dnajb1–Prkaca Fusion
Three guide (g)RNAs were designed to target intron 1 of
either mouse Dnajb1 or mouse Prkaca and introduced into
pX330-U6-chimeric_BB-CBh-hSpCas9 vector that co-expresses
gRNA driven by U6 promoter and Cas9 driven by chicken
b-actin hybrid promoter14 (Addgene plasmid #42230). Neuro-
2a cells were transfected with the individual pX330 gRNA/
Cas9 constructs along with empty pSpCas9(BB)-2A-GFP
vector15 at a 6:1 molecular ratio to mark transfected cells
with GFP (green ﬂuorescent protein), using X-tremeGENE
HP transfection reagent according to the manufacturer’s
instructions (Sigma-Aldrich, St. Louis, MO). Two days post-
transfection, we analyzed the efﬁciency of the gRNA
designs using our protocol for genome editing using FACS
(ﬂuorescence-activated cell sorting) enrichment of nuclease
expressing cells and indel detection by amplicon analysis
(IDAA).16 Brieﬂy, the top 10% most GFP ﬂuorescent cells were
isolated by FACS and lysed to 2000 cells/mL in QuickExtract
DNA extraction solution (Epicentre, Madison, WI). One-mL cell
extract was used as template in a tri-primer genomic polymerase
chain reaction (PCR) with locus-speciﬁc IDAA Fwd and Rev
primers that ampliﬁed the gRNA target site and a common
FamFwd primer identical to an overhang on the Fwd primer,
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used in this study are provided in Supplementary Table 1).
Subsequent analysis of amplicons in a 3500 Genetic Analyzer
(Thermo Fisher) revealed the size and frequency of insertion
and deletion (indel) mutations elicited by the gRNA designs.
To test the ability of the gRNA constructs to generate the
Dnajb1–Prkaca fusion, Neuro-2a cells were co-transfected with
combinations of pX330 pairs targeting intron 1 of Dnajb1 and
Prkaca, using X-tremeGENE HP transfection reagent. Three
days post-transfection, total RNA was extracted using QIAsh-
redder spin columns (Qiagen, Ballerup, Denmark) and RNeasy
Mini Kits (Qiagen). Total RNA was reverse transcribed using
TaqMan Reverse Transcription Reagents (Thermo Fisher Sci-
entiﬁc, Waltham, MA) and analyzed by PCR using the primers
Dnajb1–RT-Fwd and Prkaca-RT-Rev that amplify the junction of
the Dnajb1–Prkaca fusion cDNA. In addition, genomic DNA was
extracted and PCR ampliﬁed with the primers Dnajb1–Fwd1
and Prkaca–Rev1 that amplify the Dnajb1–Prkaca junction and
resulting PCR products were cloned and Sanger sequenced to
determine the sequence of the CRISPR/Cas9-induced genomic
breakpoint. Amplicons were further analyzed by IDAA using the
primers Dnajb1–intron1-IDAA-Fwd and Prkaca–intron1-IDAA-
Rev to determine the number and frequency of different fusion
alleles present in the population.
CRISPR/Cas9 Engineering of Dnajb1–Prkaca
in the Adult Mice Liver
The pair of pX330 gRNAs that appeared most optimal with
respect to generating the Dnajb1–Prkaca fusion in vitro was
delivered to the liver of adult mice via hydrodynamic tail vein
injection, which was performed essentially as previously
described.17,18 Brieﬂy, 8-week-old female FVB/N mice (FVB/
NRj, Janvier Labs, Le Genest Saint Isle, France) were anes-
thetized with isoﬂurane (Abbott, Copenhagen, Denmark) and
hydrodynamically injected within 5–8 seconds with 50 mg of
each pX330 gRNA plasmid suspended in a volume of Ringer’s
solution corresponding to approximately 8% (vol/wt) of their
body weight. The control cohort was injected with 100 mg
of empty pX330 vector expressing Cas9 only. Animal housing
and approvals are described in the Supplementary Materials
and Methods.
Histology
Livers were ﬁxed in 10% neutral buffered formalin (Lillies
ﬁxative) for 24 hours at 4C, submersed in 70% ethanol for
24–48 hours, dehydrated in ethanol and xylene in a tissue
processor, and then embedded in parafﬁn. The livers were cut
into 3–5-mm thick sections that were mounted onto glass slides
and deparafﬁnized and rehydrated by standard procedures.
Sections were then either stained with H&E, with PicroSirius
red, with periodic-acid Schiff reagent with or without pre-
treatment with diastase or subjected to immunohistochemistry
using the following antibodies and conditions: rabbit mono-
clonal anti-cytokeratin 19 (1:200, ab52625; Abcam, Cambridge,
United Kingdom) and rabbit anti-Ki67 (1:100, ab16667;
Abcam) used with antigen retrieval in citrate buffer, pH 6.0 for
20 minutes at 98C. Rabbit monoclonal anti-cytokeratin 7
(1:100, ab181598; Abcam), rabbit polyclonal anti-
carcinoembryonic antigen (1:30, ab33562; Abcam), rabbit
polyclonal anti-carbamoyl phosphate synthetase-1 (HepPar-1)(1:50, ab3682; Abcam), rabbit polyclonal anti-glutamine syn-
thetase (1:1000, ab73593; Abcam) used with antigen retrieval
in Tris EGTA buffer, pH 9.0, for 15–20 minutes at 98. A
Shandon Sequenza slide rack system (Thermo Fisher Scienti-
ﬁc) was used to incubate sections with primary antibodies
overnight at 4C and for 45 minutes at room temperature with
EnVisionþ System Labeled Polymer–horseradish peroxidase
(HRP) anti-rabbit (#K4003, Dako, Glostrup, Denmark),
according to manufacturer’s instructions. Chromogen staining
was performed using NovaRED HRP substrate kit (VWR
International, Søborg, Denmark). All antibodies were
diluted in Antibody Diluent with Background Reducing Com-
ponents (Dako). Counterstaining was performed using Harris
haematoxylin (Histolab, Askim, Sweden).Genomic PCR of the Dnajb1–Prkaca Fusion on
Laser Capture Microdissected Tumors
Parraﬁn-embedded livers were sectioned at 5 mm thickness,
mounted on 1.0 PEN MembraneSlides (Zeiss, Jena, Germany)
and stained with H&E. Desired tissue areas were micro-
dissected onto CapSure HS LCM Caps (Thermo Fisher Scientiﬁc)
in an Arcturus PixCell II laser capture microdissection system.
Genomic DNA was extracted from the captured tissue through
incubation of the tissue for 6 hours at 65C in 10 mL proteinase
K-containing extraction buffer followed by 10 minutes at 95C
using the Arcturus PicoPure DNA Extraction Kit (Thermo Fisher
Scientiﬁc). One mL of the extract was used as template in a
multiplex PCR that simultaneously ampliﬁed the genomic
Dnajb1–Prkaca breakpoint to test for the presence of the
fusion as well as a nearby region in Prkaca that was not
affected by the editing, thereby serving as an internal PCR
control. PCR conditions are provided in the Supplementary
Materials and Methods.
Additional methods can be found in the Supplementary
Materials and Methods.Results
CRISPR/Cas9-mediated engineering of
Dnajb1–Prkaca In Vitro and In Vivo
In the mouse genome, Dnajb1 and Prkaca are located on
chromosome 8 in a region syntenic to human chromosome
19. To engineer in mice the complex chromosomal rear-
rangement that generates DNAJB1–PRKACA in human
FL-HCC, we made use of CRISPR/Cas9 technology. In our
approach, gRNAs were designed to target Cas9 to intron 1 of
murine Dnajb1 and intron 1 of murine Prkaca and thereby
introduce DNA double-strand cuts in the regions, where
chromosomal breaks occur in the vast majority of human
FL-HCC analyzed (Figure 1A).7 When co-introduced in
cells, we expected the CRISPR/Cas9 reagents to excise the
desired w400 Kb genomic DNA fragment, and the cellular
repair machinery to join the DNA ends and create the
Dnajb1–Prkaca fusion, as occurring in human FL-HCC.
Thus, we ﬁrst engineered constructs expressing Cas9
and guide (g)RNA in the pX330 vector14 targeting either
Dnajb1 intron 1 or Prkaca intron 1 and assayed their efﬁ-
ciency in generating cuts at the respective target sites 2 days
after their individual transfection into mouse Neuro-2a cells.
Figure 1.Generation of CRISPR/Cas9 reagents that engineer the Dnajb1–Prkaca fusion in vitro and in adult mouse liver. (A) In
the mouse genome, Dnajb1 and Prkaca are located on chromosome 8 in a region syntenic to human chromosome 19. The
target sequences and locations of the gRNA pair used to engineer the Dnajb1–Prkaca fusion are shown. (B) Ability of the gRNA
pair shown in (A) to engineer the Dnajb1–Prkaca fusion in transfected Neuro-2a cells. (Left) Schematic of the Dnajb1–Prkaca
genomic fusion and location of primers (arrows) used to amplify the breakpoint. Sanger sequencing chromatogram and se-
quences for various fusion breakpoints are shown. “Predicted” sequence indicates gene fusion without any indel mutagenesis.
(Right) IDAA proﬁle showing the frequency of the various breakpoint amplicons. (C) Ability of the gRNA pair shown in (A) to
engineer the Dnajb1–Prkaca fusion in the liver of hydrodynamically tail vein injected mice. (Left) Dnajb1–Prkaca speciﬁc PCR
from cDNA derived from the liver of mice injected with the gRNA pair. (Right) Schematic of the fusion transcript and location of
primers (arrows) used to amplify the fusion breakpoint. The Sanger sequencing chromatogram demonstrates an in-frame
fusion transcript.
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frequency of indel mutations generated by the cellular DNA
repair machinery as a measure of the cutting efﬁciency of
our CRISPR/Cas9 constructs (Supplementary Figure 1A).
Next, we co-transfected the various construct pairs into
Neuro-2a cells and assessed their ability to generate the
Dnajb1–Prkaca fusion 3 days post-transfection. Analysis of
genomic DNA and reverse-transcribed RNA by PCR and
Sanger sequencing of the amplicons demonstrated the
presence of the intended chromosomal rearrangement and
the expression of the proper fusion transcript (Figure 1B,
Supplementary Figure 1B).
Having conﬁrmed the feasibility of our approach to
engineer the desired chromosomal rearrangement in vitro,
we combined our CRISPR/Cas9 reagents with hydrody-
namic delivery in an attempt to create the Dnajb1–Prkaca
aberration in the liver of young adult mice. Thus, we
hydrodynamically tail vein injected 8-week-old mice with
our most optimal CRISPR/Cas9 plasmid pair targeting
Dnajb1 and Prkaca, or with empty pX330 control plasmid.
Three days post-injection, the mice were sacriﬁced and
their livers analyzed. Genomic DNA and mRNA analyses
showed the presence of the Dnajb1–Prkaca fusion and
detectable levels of fusion transcript in mice injected
with the CRISPR/Cas9 plasmid pair (Figure 1C and
Supplementary Figure 1C). We estimated that the fre-
quency of the Dnajb1–Prkaca genomic fusion was approx-
imately 0.7–1.5 copy/100 cells in the CRISPR/Cas9 edited
livers (data not shown).The Dnajb1–Prkaca Fusion Induces FL-HCC
in Mice
A cohort of 8-week-old wild-type mice was hydrody-
namically tail vein injected with the CRISPR/Cas9 plasmid
pair for generation of the Dnajb1–Prkaca aberration or with
empty pX330 control plasmid. Mice were sacriﬁced 14
months post-injection at the time when some of the mice
showed signs of distress and their livers analyzed for the
presence of alterations. Twelve out of 15 (80%) CRISPR/
Cas9-injected mice and 0 of 11 control-injected mice
presented oncogenic lesions in the liver parenchyma that
varied in size (Figure 2, Supplementary Figure 3). Mouse
FL-HCC driven by the fusion showed most of the speciﬁc
cytologic and histologic features of human FL-HCC, as
illustrated by a large brownish and fully surfaced tumor
(10–12 mm) shown in Figure 2A. As in human, mouse
FL-HCC appears as a relatively well-circumscribed mass
with pushing margin against the non-tumorous tissue, and
composed of solid sheets and tightly packed cords and
trabeculae of large polygonal hepatocyte-like cells separated
by variably dilated sinusoids. Furthermore, tumor cells
contained large nuclei with coarse chromatin and 1 or more
prominent nucleoli (Figure 2B and 2C)19,20, and their
abundant cytoplasm was characteristically granular and
eosinophilic in analogy with the “oncocyte-like” aspects
of the mitochondria-rich cytoplasm in cells of human
FL-HCC.21 Indeed, ultrastructural analysis obtained bytransmission electron microscopy conﬁrmed the presence of
tightly packed mitochondria in cells from mouse FL-HCC
and also evidenced the characteristic nuclear morphology
of these oncocytic hepatocytes22,23 (Figure 2D and
Supplementary Figure 2A). Additionally, tumor cells con-
tained inclusions resembling the intracellular “pale bodies”
as well as the hyaline globules often observed in human
FL-HCC (Figure 2C, Supplementary Figure 2B), and accord-
ingly, these globules contained material that was positive
for the periodic acid-Schiff stain and sensitive to diastase
enzymatic digestion (Figure 2E, and data not shown).1
Importantly, the tumor was positive for the intended
CRISPR/Cas9-induced Dnajb1–Prkaca fusion and expressed
the chimeric in-frame transcript, as demonstrated by
genomic DNA and reverse transcribed mRNA sequencing
(Supplementary Figure 2C). No sign of off-target cutting
elicited by the CRISPR/Cas9 tools was evident in the top-
ranking predicted off-target sites for both gRNAs,24 as
assessed by IDAA (Supplementary Figure 2D and data
not shown).
The smaller neoplastic lesions (<1 mm) were also
characterized by the distinctive “oncocytic” hepatocytes
described in human FL-HCC. As observed for the large cells
that constitute both human and murine FL-HCC, the “onco-
cytic” hepatocyte-like cells in these lesions were also large,
also contained granular eosinophilic-orange cytoplasm,
large nuclei, and prominent nucleoli (Figure 2F and
Supplementary Figure 3B). Such oncocytic cells were also
present in transition areas between the large tumor shown
in Figure 2A and the surrounding non-tumorous tissue,
hence supporting the notion that these foci represent pre-
cursor lesions for FL-HCC. The small lesions often showed
various degrees of leukocyte inﬁltration inside and around
the foci (Figure 2F and Supplementary Figure 3B). All the
large and small Dnajb1–Prkaca-elicited lesions showed the
cytologic characteristics of FL-HCC described above. Only 1
lesion, in fact, contained premalignant clear cells inter-
mingled with oncocytic hepatocytes with prominent nucleoli
and eosinophilic cytoplasm (Supplementary Figure 3C), in
accordance with the observation that FL-HCC may occa-
sionally appear as a mixed-FL-HCC, which has also been
reported positive for the fusion.25 Genomic DNA analysis
of laser capture microdissected small lesions conﬁrmed
the presence of the oncogenic Dnajb1–Prkaca aberration
(Supplementary Figure 3D).
PicroSirius red staining for collagen showed mild
thickening of the collagen connective tissue network
accompanying the tumor cells (Figure 3A), whereas the
non-tumorous liver parenchyma was completely devoid of
ﬁbrotic change (Supplementary Figure 4A). The collagen
bands in murine FL-HCC were not as thick as in human
FL-HCC and no large, central collagen scar was observed,
which however is consistent with the limited tendency of
mouse liver to develop collagen ﬁbrosis without chemical
challenge.26
Immunohistochemical characterization showed that
mouse FL-HCC elicited by Dnajb1–Prkaca expresses both
hepatocyte and cholangiocyte markers, as reported for
Figure 2. The Dnajb1–
Prkaca fusion induces FL-
HCC in mice. Representa-
tive macroscopic and
microscopic images of
mouse FL-HCC elicited by
Dnajb1–Prkaca. (A)
Macroscopic image of a
tumor (arrow). (B) Whole-
scan H&E image and
magniﬁcation showing
tumor (Tu)-non-tumor (N)
border. (C) Microscopic
H&E image of tumor area
showing trabeculae of
tumor cells separated by
variably dilated sinusoids.
(Upper inset) Detail of an
“oncocytic” tumor cell with
granular eosinophilic
cytoplasm and large
nucleus with prominent
nucleolus. (Lower inset)
Detail of “pale body” and
hyaline globulus. (D)
Transmission electron
micrograph of tumor cell
showing cytoplasm
packed with mitochondria
(arrows) and nucleus with
prominent nucleolus and
coarse chromatin. (E) Pe-
riodic acid-Schiff staining
of hyaline globules. (F)
Small neoplastic lesion
with large oncocytic cells
with granular eosinophilic
cytoplasm and prominent
nucleoli (black arrow) and
leukocyte inﬁltration (white
arrow).
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the hepatocytic markers hepatocyte parafﬁn 1 (HepPar1)
and carcinoembryonic antigen (CEA) with a canalicular
distribution (Figure 3B and C), as frequently observed in
human FL-HCC.5,11 Furthermore, mouse FL-HCC showed
scattered expression of cytokeratin 7 and cytokeratin 19
(Figure 3D and E), 2 markers that are frequently and
occasionally expressed, respectively, by human FL-HCC,5,11
whereas in normal liver these proteins are present
only in the cholangiocytes of the bile ducts and in
hepatic progenitor cells (Supplementary Figure 4B and C).
Finally, mouse FL-HCC expressed glutamine synthetase
(Figure 3F), which occurs in both HCC and chol-
angiocarcinoma with similar frequency,27 whereas in
normal liver only hepatocytes adjacent to the central vein
are positive (Supplementary Figure 4D).Molecular Analysis Supports Dnajb1–Prkaca
as the Key Driver of Initiation and Progression
of FL-HCC
To gain further insight into the mechanisms underlying
neoplastic transformation induced by Dnajb1–Prkaca, we
performed transcriptomic and genomic analyses of the
lesions. RNA-seq analysis of total RNA isolated from a tu-
mor where freshly frozen tissue was available and from
freshly frozen tissue from control injected mouse livers
conﬁrmed the expression of the proper Dnajb1–Prkaca
fusion transcript in the tumor, with juxtaposition of exon 1
of Dnajb1 to exon 2 of Prkaca (Figure 4A and
Supplementary Table 2). Gene set enrichment analysis
(GSEA) of the differentially expressed genes between tu-
mor and liver control against the Molecular Signatures
Database (Broad Institute, C5.bp), revealed a robust
Figure 3. Histologic char-
acterization of Dnajb1–
Prkaca elicited mouse
FL-HCC. (A) PicroSirius
red staining showing mild
collagen ﬁbrosis between
tumor cells. (B) Tumor
cells express HepPar1.
(Inset) Detail of a tumor cell
expressing HepPar1 with
mitochondrial localization
and illustrating the
mitochondria-rich cyto-
plasm. (C) CEA staining
showing canalicular distri-
bution in tumor area (Tu),
as well as in normal liver
area (N). (D) Cytokeratin 7
expression in tumor area.
(E) Cytokeratin 19 expres-
sion in tumor area. (F)
Broad expression of
glutamine synthetase by
tumor cells (Tu), but not by
hepatocytes of the normal
liver area (N).
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control and mitosis regulation, and a down-regulation of
genes involved in regulation of metabolic processes (GSEA:
false discovery rate (P value, <.05) (Supplementary
Tables 3, 4, and 5). Further results for positively and
negatively regulated enriched gene sets are presented in
Supplementary Tables 6 and 7.
Several studies have contributed to the characterization
of the transcriptomic proﬁle of human FL-HCC by
comparing expression data from tumor specimen with that
of normal liver or with that of other liver cancers.10,11,28–30
We compared the differentially expressed genes between
mouse FL-HCC and normal mouse liver with those from3 different human FL-HCC studies8,11,29 and identiﬁed a
strong enrichment (GSEA: familywise error rate adjusted
P value, <.001) of mouse FL-HCC genes in the down-
regulated and up-regulated gene sets from these human
studies, thus further conﬁrming the resemblance of mouse
tumor to human FL-HCC (Supplementary Figure 5A). In
particular, common differentially expressed genes between
RNA-seq data from human29 and mouse FL-HCC include
directionally concordant genes involved in cell cycle and
mitosis regulation processes (Figure 4B) (list of genes pro-
vided in Supplementary Tables 8 and 9). The mouse FL-HCC
transcriptome also displayed a proﬁle closest resembling
that of mature hepatocytes as evidenced by a comparison
Figure 4.Molecular anal-
ysis of Dnajb1–Prkaca eli-
cited mouse FL-HCC. (A)
Sashimi plot of RNA-seq
read coverage for Dnajb1
and Prkaca in normal liver
and mouse FL-HCC.
Peaks depict reads per
kilobase per million reads
mapped (RPKM). Arcs de-
pict reads spanning splice
junctions. (B) Venn Dia-
gram showing overlap of
differentially expressed
genes between human
(Simon et al29) and mouse
FL-HCC. Differentially
expressed genes for
mouse FL-HCC were
deﬁned by a BaseMean
value >25 and log2FC
>1.5 over normal liver.
Gene Ontology Biological
Process (MSigDB, c5.bp)
is shown for the 145
common differentially
expressed genes, showing
enrichment of mitosis and
proliferation genes. (C)
Immunoblotting of tissue
lysates from mouse
FL-HCC tumor (Tu), adja-
cent normal liver (N) or
livers from control mice.
PKAc, immunoblotting
using an antibody raised
against the catalytic sub-
unit alpha of PKA. Vinculin
is used as loading control.
(D) Ki67-staining of tumor
cells (Tu) and adjacent
normal tissue (N). Bars
represent quantiﬁcation of
Ki67-positive cells/number
of hepatocytes.
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literature31 (Supplementary Figure 5B).
Notably, human FL-HCC was reported to express high
levels of the cytokinesis and mitosis regulator Aurora kinase
A29,30 and a clinical trial is ongoing to test the efﬁcacy of its
inhibition in FL-HCC patients.32 Our RNA-seq data and
immunoblotting of tissue lysate from mouse FL-HCC tumor
showed high expression of Aurora kinase A, as compared
with the non-tumorous area of the liver and control-injected
livers (Supplementary Table 3 and Figure 4C) and, as
expected, expression of the DNAJB1–PRKACA fusion protein,
thus further corroborating the rationale of targeting Aurora
kinase A in clinical trials. Moreover, tumors showed a high
proliferation index revealed by Ki67 staining, as opposed to
normal hepatocytes in the adjacent non-tumorous areas
(Figure 4D, Supplementary Figure 3A).Human FL-HCC has been concordantly shown to have a
relative stable genome with fewer mutations than other
liver cancers and, with the exception of the DNAJB1–PRKACA
fusion, no known liver cancer genes are recurrently
altered.8,11,12,33 These ﬁndings prompted us to analyze the
mutational load of our CRISPR/Cas9 generated mouse
FL-HCC. We therefore performed Whole-exome sequencing
(WES) of paired normal liver and mouse FL-HCC (for 1
larger and 1 smaller tumor) to identify genomic alterations
that could have contributed to tumorigenesis instigated by
Dnajb1–Prkaca. A total of 80 single nucleotide variants
(SNVs) and 1 deletion were identiﬁed in the larger tumor
(Supplementary Figure 6A and Supplementary Table 10): of
these, 35 were non-synonymous (Supplementary Figure 6B)
that we scored for their potentially damaging effect using
Polyphen2.34 Importantly, only 1 gene with a damaging SNV
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which is involved in alcohol catabolism). Although an
ALDH2 polymorphism (rs 671, missense mutation E457K)
has been associated with increased susceptibility to alcohol-
induced gastrointestinal cancer in East Asians,35 it is
perhaps not so likely that the Aldh2 SNV identiﬁed here
contributes to Dnajb1–Prkaca-elicited FL-HCC in the present
mouse setting. We Sanger sequenced the mutated region of
most of those genes expressed, as evidenced by the RNA-seq
data, and harboring predicted deleterious mutations, and
conﬁrmed the presence of SNVs in 8 cases (Supplementary
Table 10). We also conﬁrmed by IDAA the 3 basepair
intronic deletion identiﬁed in 1 gene (Supplementary
Figure 6C). Importantly, none of the mutated genes were
reported mutated in any of the human FL-HCC genomic
studies, nor have these genes been found consistently
mutated in human liver cancers or are obvious cancer
drivers (Supplementary Table 10). The mutational load
of the smaller tumor was characterized by fewer SNVs
(9) than the larger tumor described above, and it
conﬁrmed the absence of recurrent mutations or mutations
in known cancer genes in FL-HCC induced by Dnajb1–
Prkaca, and supported the idea that the number of muta-
tions in a tumor increases as a consequence of its evolution
(Supplementary Table 11). Interestingly, only 1 indel
mutation site with no resemblance to the gRNAs used was
detected by the WES, demonstrating that CRISPR/Cas9 off-
target mutagenesis had not occurred within the exome of
the tumors. Lastly, of some of the most prevalently
mutated genes in other liver cancers (CTNNB1, TP53 and
KRAS)11 or in mouse models of liver cancers13 (Hras), none
were found to be mutated by targeted analysis of the
smaller lesions that we analyzed.Discussion
The aim of this study was to determine if the DNAJB1–
PRKACA fusion is oncogenic and by inference, is the causa-
tive mutation of FL-HCC. With the emerging recognition that
DNAJB1–PRKACA occurs in most, if not all FL-HCC patients,
the functional demonstration of DNAJB1–PRKACA as driver
would establish the genetic origin of this cancer.
We provided this evidence by the stringent approach
of engineering in adult mouse liver the same genomic
Dnajb1–Prkaca alteration that occurs in human FL-HCC. To
this end, we exploited the powerful CRISPR/Cas9 technol-
ogy, which was recently used to engineer the complex
genomic rearrangement that creates the well-established
oncogenic EML4-ALK fusion in mouse models of human
lung cancer.36,37 Moreover, a key point of our study is that
we engineered Dnajb1–Prkaca in wild-type mice and
without administration of any mutagens, to conclude,
upon tumor formation, that DNAJB1–PRKACA is the main
driving mutation. Finally, our engineering of the aberration
in a healthy mouse liver and, at a low frequency, are
important additional features of our study that mimic the
stochastic and rare events leading to tumor initiation in
FL-HCC patients in absence of other liver disease. The
development of neoplastic lesions in the majority of ourCRISPR/Cas9-engineered mice demonstrated that Dnajb1–
Prkaca is sufﬁcient to induce FL-HCC and thus is the main
genetic event that initiates this cancer. The tumor latency of
>1 year in our FL-HCC model is not unusual for a single
genetic alteration in mouse liver cancer models,13 and is
consistent with the notion that FL-HCC is considered to be
a slowly progressing liver cancer in humans.21
Importantly, the lesions induced by Dnajb1–Prkaca in
mice had a high resemblance with human FL-HCC. Gross-
anatomically, the tumors were well circumscribed from
adjacent normal liver tissue as seen for human FL-HCC.
Perhaps most strikingly, the cytologic characteristics of
mouse FL-HCC were highly similar to those of human
FL-HCC, which are used as major diagnostic features in
the clinic (reviewed in Torbenson1, and in Ward and
Waxman33). Indeed, mouse lesions were composed of un-
usually large, polygonal tumor cells, often presenting
prominent macronucleoli and with an abundant granular
eosinophilic cytoplasm characteristic of oncocytic hepato-
cytes. The cytologic appearance of these oncocytic hepato-
cytes is because of the presence of densely packed
mitochondria, as evidenced by ultrastructural examination
of both human and mouse FL-HCC in electron microscopy
studies. Mouse lesions also showed, as observed in nearly
half of human FL-HCC, hyaline globules and round cyto-
plasmatic inclusions known as “pale bodies.”1 It therefore
appears that Dnajb1–Prkaca has the cell-autonomous
capacity to elicit all the characteristics of the FL-HCC cell
phenotype, both in mouse and human.
In one respect mouse FL-HCC did not fully recapitulate
the human tumor. Although collagen ﬁbrosis was observed,
it was considerably less pronounced than in human FL-HCC,
where it sometimes forms a large, central scar. The limited
ﬁbrosis may not be surprising because mouse livers are
known to display an attenuated ﬁbrotic response, as
observed in mouse models of cancer as well as liver
ﬁbrosis.13 Little is known about how ﬁbrosis is elicited in
FL-HCC, nor is there any evidence that the collagen depo-
sition has any role in the progression of FL-HCC. The
present study suggests that FL-HCC arises and progress
through a cell autonomous action of Dnajb1–Prkaca within
the tumor cells, which does not depend on ﬁbrosis in
the tumor.
Mouse FL-HCC also resembles human FL-HCC by
expressing both hepatocytic and cholangiocytic markers as
evidenced by immunohistochemical characterization.
Although widely used in clinical practice, none of the pro-
posed markers are actually speciﬁc for FL-HCC and their
diagnostic signiﬁcance is therefore limited.38 Mouse FL-HCC
expressed high levels of hepatocytes markers (CEA and
HepPar1) and displayed scattered positivity for the biliary
epithelium marker cytokeratin 7 and a stronger staining
for cytokeratin 19, a marker associated with both biliary
differentiation and hepatic progenitors. Mouse FL-HCC
failed to show staining for CD68, which has been shown
to be expressed in human tumors (data not shown).39
Transcriptomic analysis of mouse FL-HCC revealed
similarities with human FL-HCC as well as differences. In
fact, we did not identify in our dataset previously reported
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signature, as these genes were either expressed at a very
low level or were not differentially expressed. An exception
was carboxypeptidase, which we found up-regulated
(Supplementary Table 3), in agreement with Xu et al.8
However, although overexpression of some of these genes
has been observed in several studies,8,11,28,29 gene signa-
tures have failed to consistently mark FL-HCC as a tumor of
neuroendocrine origin.29,33 Species differences in gene
expression between human and mouse may explain the
lack of select FL-HCC features, most notably the lamellar
bands of ﬁbrosis, in the murine tumor. However, a strong
enrichment in directionally concordant differentially
expressed genes in mouse and human tumor was evidenced
by cross-species GSEA.
In mouse FL-HCC we conﬁrmed the increased expression
of Aurora kinase A, a mitotic serine/threonine kinase
involved in cell cycle progression and implicated in
tumorigenesis, which was recently reported up-regulated
in 2 human FL-HCC studies.29,30 This ﬁnding may be
important in light of the ongoing clinical trial aimed at
testing Aurora kinase A inhibition in FL-HCC patients; also
in that it identiﬁes a common pathologic event initiated by
DNAJB1–PRKACA in both human and mouse FL-HCC, which
represents an attractive therapeutic target.40
It remains unclear to what extent, if any, mutations other
than the DNAJB1–PRKACA aberration contribute to FL-HCC.
Prior to the discovery of DNAJB1–PRKACA, driver genes
were searched for using comparative genomic ampliﬁcation
analyses or focused analyses of genes known to underlie
other liver cancers, which, however, did not identify any
plausible FL-HCC drivers.33 After the discovery of DNAJB1–
PRKACA, 2 studies performed whole-exome sequencing on a
single tumor containing the fusion,8,11 the latter extending
the analysis of a few mutated genes to a larger FL-HCC
tumor collection. The 2 studies identiﬁed relatively few
coding mutations (11 and 90), which showed no overlap,
were infrequently considered damaging, and did not affect
known cancer genes, except for BRCA2, which was found
mutated in 4.2% of FL-HCC samples in the extended anal-
ysis. Another study performed whole-genome sequencing of
10 FL-HCC patients and found no recurrent structural
variants other than DNAJB1–PRKACA, few coding mutations
per tumor (a median of 6) and some genes being recurrently
mutated of which the signiﬁcance was unclear.12 The
authors concluded that the lack of second-hit mutation in
FL-HCC makes the DNAJB1–PRKACA fusion protein the best
target for diagnostic and therapeutic advancement. Our
study agrees with the human studies, as we found no rele-
vant coding mutations in known driver genes for liver
cancers or other malignancies.
Regardless of the possible involvement of other genes,
our ﬁnding that DNAJB1–PRKACA is sufﬁcient to elicit
FL-HCC combined with its ubiquitous presence in FL-HCC
patients ﬁrmly establish DNAJB1–PRKACA as the dominant
genetic driver of this cancer. Indeed, testing of DNAJB1–
PRKACA mRNA or protein as a drug target in FL-HCC
is highly warranted.38 DNAJB1–PRKACA could prove as
excellent a drug target as the BCR-ABL1 fusion in chronicmyeloid leukemia, where a single, oncogenic event elicits
and drives the disease and predicts a very favorable
response to its inhibition.41 This scenario would require
that, once formed, FL-HCC tumors remain addicted to
DNAJB1–PRKACA for growth and survival. FL-HCC mouse
models generated as described here, along with a recently
established FL-HCC transplantable tumor line,42 might
constitute preclinical settings where the DNAJB1–PRKACA
fusion could be tested as a drug target in FL-HCC.
In summary, we report the ﬁrst CRISPR/Cas9-
engineered mouse model of liver cancer generated somati-
cally by a single oncogenic modiﬁcation in otherwise
wild-type mice and without administration of toxin or
carcinogen. Furthermore, we describe the ﬁrst mouse model
of FL-HCC, notably one that replicates to a high extent the
genotype and phenotype associated with this human cancer.
Importantly, our study demonstrates that the recently
identiﬁed DNAJB1–PRKACA fusion is the cause of FL-HCC,
and is responsible for oncogenic transformation and major
pathodiagnostic features of this cancer. Our ﬁndings thereby
provide strong support for DNAJB1–PRKACA as a target for
new therapies in FL-HCC and our mouse model may be
useful to study the initiation and progression of FL-HCC as
well as pre-clinical testing of new treatments.
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Supplementary Materials and Methods
Animal Housing and Approvals
Mice were housed in Green line type II IVC plastic cages
(Tecniplast, Buguggiate, VA, Italy) in a temperature-
controlled pathogen-free animal facility, with unrestricted
access to diet (Altromin #1324, Altromin, Lage, Germany)
and tap water. The animal room had a 12:12 hour light-dark
cycle (lights on at 06.00). Mice were given nesting material,
shredded paper strips, and shelters as environmental
enrichment. Bedding was aspen wood chips supplied by
Tapvei (TAPVEI OÜ Tapvei, Estonia). The experiments were
approved by the Danish Experimental Inspectorate (proto-
col approval #2013-15-2934-00986) and housing of the
mice was carried out according to Danish legislation and
the Directive 2010/63/EU on the protection of animals used
for scientiﬁc purposes.
Estimation of the Efﬁciency of Engineering
Dnajb1–Prkaca In Vivo
Livers were collected 3 days after hydrodynamic tail
vein delivery of CRISPR/Cas9 plasmids and genomic DNA
was extracted using QIAmp DNA Mini Kit (Qiagen)
following manufacturer’s instruction. We ﬁrst conﬁrmed
the generation of the Dnajb1–Prkaca fusion by PCR
ampliﬁcation of the genomic breakpoint using HotStar
Master Mix Kit (Qiagen) and Dnajb1–Fwd1 and Prkaca-
Rev1 as primer pair. Next, we estimated the number of
copies of the Dnajb1–Prkaca allele in the genomic DNA. To
this end, we PCR ampliﬁed serial dilutions of a genomic
DNA sample containing the Dnajb1–Prkaca fusion and
quantiﬁed the intensity of each PCR amplicon run on a
2% agarose gel with ImageJ software (http://rsbweb.nih.
gov/ij/). With these data we generated a calibration
curve that was used to estimate the number of copies of
Dnajb1–Prkaca by measuring the intensity of amplicons
generated by PCR on genomic DNA from the liver of the
hydrodynamically injected mice.
Transmission Electron Microscopy
Formalin-ﬁxed and parafﬁn-embedded tumor and
matched liver samples were de-parafﬁnized with xylene ac-
cording to standard procedures and immersed in 2% v/v
glutaraldehyde in 0.05 mol/L sodium phosphate buffer
(pH7.4) over night. Sampleswere rinsed 3 times in 0.15mol/L
sodium phosphate buffer (pH 7.4) and subsequently postﬁxed
in 1% w/v OsO4 and 0.05 mol/L potassium ferricyanide in
0.12 mol/L sodium phosphate buffer (pH 7.4) for 2 h. The
specimens were dehydrated in graded series of ethanol,
transferred to propylene oxide, and embedded in Epon ac-
cording to standard procedures. Sections, approximately 80-
nm thick, were cut with a Leica UC7 microtome and
collected on copper grids with Formvar supporting mem-
branes. Sections were stained with uranyl acetate and lead
citrate and subsequently examinedwith a Philips CM100 TEM
(Philips, Eindhoven, The Netherlands), operated at an
accelerating voltage of 80 kV. Digital images were recorded
with an OSIS Veleta (Muenster, Germany) digital slow scan
2k  2k CCD camera and the ITEM software package.
Genomic CRISPR/Cas9 Off-Target Analysis
Potential off-targets for the gRNA targeting Dnajb1
intron 1 and for the gRNA targeting Prkaca intron 1 that
were used in this study to generate the Dnajb1–Prkaca
fusion were identiﬁed by using the online program http://
crispor.tefor.net/crisporDev/crisporBeta/crispor.py.
(Haeussler et al, Genome Biology, 2016;17:148) This
program ranks potential off-target sites according to a score
for probability of cutting. Nine predicted off-target sites for
the Dnajb1 gRNA and 10 predicted sites for the Prkaca
gRNA with the highest score were chosen for further anal-
ysis by IDAA. A list of the analyzed off-targets and PCR
primers used for IDAA is given in Supplementary Table 1.
IDAA was performed as described elsewhere in this manu-
script on normal vs tumor-matched genomic DNA, with
the normal DNA serving as a control. The ampliﬁed PCR
fragments were run on an ABI 3500 genetic analyzer to
identify possible indels in the off-target site of interest.
Genomic PCR of the Dnajb1–Prkaca Fusion on
Laser Capture Microdissected Tumors
The genomic region encompassing the Dnajb1–Prkaca
breakpoint was ampliﬁed by a 2-step nested PCR using
the primer pairs Dnajb1–Fwd1/Prkaca–Rev1 in the ﬁrst
step and Dnajb1–Fwd2/Prkaca–Rev2 in the second step.
The non-edited Prkaca region was co-ampliﬁed using
the primers Prkaca–Fwd3/Prkaca–Rev3 in both steps. The
template in step 2 was 1 mL of the step 1 PCR. The cycle
conditions of step 1 were: initial denaturation for 15 min at
95C, then 15 touchdown cycles of denaturation for 30 s at
95C, annealing for 30 s at 72C (with a decrease in
temperature by 1C in each cycle) and extension for 30 s at
72C, then 15 cycles with same conditions except that
the annealing temperature was constant at 58C followed
by a ﬁnal extension step for 5 min at 72C. In step 2,
identical cycle conditions were used, except for 25 cycles
in the ampliﬁcation step. PCR was performed in 25 mL
with ﬁnal concentrations/amounts of reagents as follows:
1.2 U TEMPase Hot Start DNA polymerase (Ampliqon,
Odense, Denmark), 1x ammonium buffer with 2.5 mmol/L
MgCl2 (Ampliqon), 1 mmol/L dNTP (Ampliqon), and 0.25
mmol/L of each primer. Ampliﬁcation of PCR products of
the proper size was veriﬁed by agarose gel electrophoresis.
Finally, fusion PCR products were cloned and Sanger
sequenced to determine the sequence.
mRNA Expression Proﬁling
Freshly dissected tumor or normal liver tissues from
control-injected mice were snap-frozen in liquid nitrogen.
Total RNA was extracted from the tissue using QIAshredder
spin columns (Qiagen) and RNeasy Mini Kits (Qiagen) and
RNA integrity number was determined in an Agilent Tech-
nologies 2100 Bioanalyzer using the Agilent RNA 6000 Nano
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kit (Agilent Technologies, Glostrup, Denmark). Libraries for
RNA sequencing were prepared using the NEBNext Ultra
Directional RNA Library Prep Kit for Illumina (NEB #E7420)
and NEBNext rRNA Depletion Kit (NEB #E6310), according
to the manufacturer’s instructions (New England Biolabs,
Ipswich, MA). Library quality was assessed in an Agilent
Technologies 2100 Bioanalyzer using the Agilent DNA 1000
kit (Agilent Technologies), quantiﬁed using the Qubit dsDNA
HS assay kit (Thermo Fisher Scientiﬁc) and diluted before
sequencing on an Illumina NextSeq 500 sequencing plat-
form. The raw data was converted from bcl to fastq format
and the samples demultiplexed using the Illumina command
line tool bcl2fastq v2.18.0.12.
Raw reads in fastq format were quality assessed with
FastQC1 and Fastq Screen2 and afterwards trimmed
using Trimmomatic v0.323 (non-default settings: -phred33
HEADCROP:12 LEADING:3 TRAILING:3 SLI-
DINGWINDOW:4:15 MINLEN:25). The trimmed reads
were aligned to the mouse (mm10 assembly) genome
with the STAR alignment tool v2.5.1a4 (non-default
settings: –readFilesCommand zcat –sjdbGTFﬁle <GTF>
–sjdbOverhang 63 –twopassMode Basic –outSAMtype
BAM SortedByCoordinate –outSAMattributes All
–outSAMunmapped Within –outFilterMismatchNoverLmax
0.1 –outFilterMatchNmin 16 –outFilterMismatchNmax 5).
Uniquely mapped reads were assigned to RefSeq database
genes (gtf format, downloaded from University of California
Santa Cruzwith date stampOct 2nd 2016)with featureCounts
v1.5.15 (none-default settings: -T 10 -s 2 -J –donotsort). Both
genome and gene annotation was limited to the canonical
genome sequences. The raw gene counts were imported into
the statistical software R (v3.3.1),6 counts from technical
replicates merged and further processed and analyzed using
the DESeq2 R-package (v1.14.1).7 Because no biological
replicates were available, no statistical tests were performed,
but based on normalized and variance-stabilized counts
(’rlogTransformation’), a simple log2 fold change was
calculated.
The Sashimi plot was constructed with the Miso package
(v0.5.3)8 and is based on 1 normal liver and the FL-HCC
sample alignment ﬁles. In addition, we compared our
expression data to previously published studies, either
through GSEA for human FL-HCC data (Cornella et al,9
Simon et al,10 Xu et al11) or through direct comparison
with mouse tissue expression data (Lee et al12). We chose to
compare with the human data using only gene lists of
differentially expressed genes to bypass direct meta-
analyses cross-organism and cross-platform. Because the
Cornella et al study did not include expression results from
a comparison of normal and FL-HCC samples, we down-
loaded the raw (except for background subtraction)
expression microarray data (GSE57725) and reanalyzed it
for our purpose. We variance-stabilized (vsn), log trans-
formed, and ﬁnally quantile normalized the background-
corrected data. Based on the sample annotation of
Dnajb1–Prkaca fusion (Present/Absent/NA) in the Cornella
et al publication Figure 5, we excluded tumor samples
where the fusion was not demonstrated and excluded
further 5 samples because of uneven quality. We performed
a standard statistical analysis on the normalized data using
the limma package (v3.30.13)13 for FL-HCC (N¼23) vs
normal (N¼3) and called differentially expressed genes with
FDR<¼5%. GSEA GseaPreranked (command-line tool v3.0)
was run with default settings on our results of genes ranked
by log2 fold change (or absolute log2 fold change). Our
ranked genes were compared with either gene sets down-
loaded from the MSigDB14 (v6) (nperm¼1000) or to the
speciﬁc FL-HCC vs Normal gene sets from Simon et al, 2015
(Data Set 1,STRICT: abs(log2fc)>¼3,baseMean>¼25), Xu
et al, 2015 (Supplementary Table 3) and Cornella et al, 2015
(FDR<¼5%) (Supplementary Figure 5A) (nperm¼10000).
For Figure 4B, we considered differentially regulated genes
as those genes with absolute log2 fold change higher than
1.5 and average normalized count (’baseMean’) above 25.
Gene Ontology analysis on directionally concordant differ-
entially regulated genes was performed using the Molecular
Signature Database (MSigDB) v6.0 from Broad Institute
(http://software.broadinstitute.org/gsea/msigdb).14
Raw transcriptomic paired-end mouse data published12
was downloaded from Gene Expression Omnibus
(GSE71873). To make the data as comparable with our data
as possible, the downloaded sequencing data was treated as
single-end reads and trimmed to the same length, but other-
wise processed identically to our own data (except s¼0 for
featureCounts). After combining gene counts of the 2 datasets
in R and normalizing for sequencing depth (’betweenLane-
Normalization’,’method¼full’) with the EDASeq package
(v2.6.2)15 we removed visible batch effect (estimated from
PCA plots) with the RUVg function (k¼1,drop¼0) from the
RUVSeq package (v1.6.2).16 The heatmap cells contain the
Spearman correlation coefﬁcients for all pairwise sample
comparisons. The symmetric row and column dendrograms
based on these correlations were calculated using Euclidian
distance and the ‘complete’ clustering method.
Whole-Exome Sequencing and SNV Validation
DNA for whole-exome sequencing was either isolated
from freshly frozen tissue or from formalin-ﬁxed parafﬁn-
embedded tumor samples. Each pair of normal and tumor
sample was derived from the same animal and the DNA was
isolated from tissue that had undergone the same ﬁxation
and storage procedure. Exome capture using SureSelectXT
Mouse All Exon Kit (Agilent Technologies) and sequencing
at a depth of >27x106 reads per sample to obtain sufﬁ-
cient coverage for mutation analysis on the Illumina
NextSeq 500 sequencer were performed by GenomeScan
(www.genomescan.nl). A pipeline based on the Genome
Analysis Toolkit (GATK) Best Practices (https://software.
broadinstitute.org/gatk/) recommendations was used
throughout the analysis. Reads were trimmed, ﬁltered, and
mapped using Burrows-Wheeler Alignment (BWA v0.7.4-
default mismatch rate of 4%) to reference assembly
(ucsc.mm9.fasta). The MuTect algorithm v1.1.417 was
used to identify somatic variants that differed between
normal and tumor DNA, and the MuTect2 algorithm was
used to identify indels. Finally, all tumor-speciﬁc SNVs
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Supplementary Figure 1. Testing of CRISPR/Cas9 reagents for engineering of the Dnajb1–Prkaca fusion. (A) Efﬁciency of the
gRNAs shown in Figure 1A to introduce a DNA double-strand break in intron 1 of Dnajb1 or intron 1 of Prkaca, as assessed by
IDAA on a pool of Neuro-2a cells transfected with the gRNAs. IDAA proﬁles show amplicons generated for wild-type (WT) and
indel mutation alleles, with indication of indel size and frequency for select amplicons. For comparison, IDAA proﬁles for non-
edited Neuro-2a cells are shown, which contain the WT amplicon only (control). (B) Dnajb1–Prkaca mRNA speciﬁc PCR on
cDNA generated from Neuro-2a cells transfected with the Dnajb1/Prkaca gRNA pair shown in Figure 1A demonstrates the
expression of an in-frame fusion transcript (Sanger sequencing chromatogram). Schematic of the fusion transcript shows the
location of primers (arrows) used to amplify the fusion breakpoint. (C) Efﬁciency of the gRNA pair shown in Figure 1A to
elicit the Dnajb1–Prkaca fusion in the liver of hydrodynamically tail vein injected mice. Dnajb1–Prkaca speciﬁc PCR from
DNA isolated from livers 3 days post injection is shown. PCR for Prkaca in a non-edited region is shown as an internal PCR
control.
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Supplementary Figure 2. The Dnajb1–Prkaca fusion elicits FL-HCC in mice. (A) Transmission electron micrograph showing
tumor cells with abundant mitochondria (arrows) in the cytoplasm and nuclei with prominent nucleoli (bottom panel), as
compared with more sparse mitochondria in hepatocytes of the non-tumorous part of the liver (top panel). (B) Microscopic H&E
image of FL-HCC tumor area with many tumor cells showing “pale bodies”, hyaline globules and features of oncocytic he-
patocytes. (C) DNA (left) and RNA (right) Sanger sequence chromatograms of the Dnajb1–Prkaca fusion derived from the tumor
in Figure 2A. Genomic and reading frame breakpoints are shown. Arrows indicate location of primers used for PCR ampliﬁ-
cation. (D) No evidence is detected of off-target cutting induced by the gRNA pair in the tumor shown in Figure 2A, as IDAA
shows only a wild-type peak at the top-ranking, predicted off-target sites for each gRNA.
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Supplementary Figure 3. Various examples of Dnajb1–Prkaca fusion induced tumors (A) Exposed tumor demarcated from the
surrounding non-tumorous liver tissue by pushing margin (upper panel) and appearing with eosinophilic, granular “oncocytic”
cells in tumor area (Tu), as compared with the normal hepatocytes of the non-tumorous area (N) (middle panel). The bottom left
panel shows details of “oncocytic” granular hepatocyte-like cells containing nuclei with prominent nucleoli (arrow), “pale
bodies” and hyaline globules (arrowhead). Ki67-staining shows that tumor cells are proliferating (bottom right panel). (B)
Examples of small neoplastic lesions with large “oncocytic” granular hepatocyte-like cells and leukocyte inﬁltration (white
arrows). (C) Mixed-FL-HCC. Lesion showing cells with features of oncocytic hepatocytes (black arrow) and cells with a clear-
cell phenotype. (D) Demonstration of the Dnajb1–Prkaca fusion in small neoplastic lesions by laser capture microdissection
and genomic PCR. A small lesion (Tu) to be analyzed (upper left). Microdissection of the lesion (Tu) and adjacent non-tumorous
tissue (N) performed on the neighboring section, which is shown after capture of the tissue (upper right). Genomic PCR on
captured tissue showing ampliﬁcation of the Dnajb1–Prkaca fusion from the lesion (Tu), but not from the normal liver tissue (N),
whereas a region in Prkaca not affected by the editing is ampliﬁed from both samples, serving as an internal PCR control
(bottom left). Sanger sequencing chromatogram for the fusion breakpoint of cloned Dnajb1–Prkaca amplicon from this tumor is
shown as an example (bottom right).
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Supplementary Figure 4. Histologic characterization of the Dnajb1–Prkaca-induced mouse FL-HCC. (A) PicroSirius red
staining showing mild collagen ﬁbrosis (red) between cells in tumor area (left), whereas in the adjacent normal liver area
collagen is conﬁned to blood vessels (right). (B) Cytokeratin 7 staining showing scattered expression in tumor cells (left), but
only expression in bile ducts in the normal part of the same liver. (C) Cytokeratin 19 expression in tumor cells (left), whereas in
the normal part of the liver, only bile ductal cells and hepatic progenitor cells are positive (right). (D) Glutamine synthetase
expression in tumor (left) and in hepatocytes adjacent to the central vein in normal liver (right).
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Supplementary Figure 5.Molecular characterization of Dnajb1–Prkaca-induced mouse FL-HCC. (A) GSEA showing negative
(left) and positive (right) enrichment plots of mouse FL-HCC in comparison with human FL-HCC transcriptomic data. For each
plot, NES (Normalized enrichment score), Nominal P value and FWER adjusted P value are indicated.
SIMON2015_FL-HCC_DOWN/UP_STRICT, XU2015_FL-HCC_DOWN/UP and CORNELLA2015_FL-HCC_DOWN/UP refer to
gene sets containing exclusively down- or up-regulated genes in references 29, 8 and 11. (B) Heat-map showing clustering of
mouse FL-HCC transcriptome with mouse biliary epithelial cells (BEC), Hepatoblasts (HB), and Hepatocytes (HP) RNA-seq
data as reported by reference 31.
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Supplementary Figure 6. Somatic mutations in mouse FL-HCC driven by Dnajb1–Prkaca. (A) Graphical representation of the
type of somatic mutations identiﬁed by whole-exome sequencing in a larger mouse FL-HCC tumor. Counts for each type of
base substitutions and for indels are indicated. (B) Pie chart depicting the distribution of the somatic mutations as Non-coding,
Synonymous, Non-sense, and Missense. The Missense mutations were classiﬁed as Possibly damaging, Probably damaging
and Benign, according to PolyPhen2 algorithm. Unclear: no damaging score available. (C) Validation by IDAA of the 3 basepair
deletion in the non-coding region of Ptdss1 from the larger mouse FL-HCC tumor. IDAA proﬁle of Ptdss1 from normal and
tumor tissue is shown. WT: wild-type peak derived from unedited allele from normal and FL-HCC tissue. The frequency of the
indel-mutated allele in the tumor is shown.
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